Skip to content
Modus Therapeutics
Developing therapeutics to restore heathy blood flow for patients with debilitating diseases
Modus Therapeutics
  • Home
  • About
  • Sevuparin
  • SIRS
  • Sepsis
  • Team
  • Investors
  • News
  • Home
  • About
  • Sevuparin
  • SIRS
  • Sepsis
  • Team
  • Investors
  • News

NEWS

Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market

Modus Therapeutics utser Sedermera Fondkommission till finansiell rådgivare i avsikt att notera företaget på Nasdaq First North Growth Market

Modus Therapeutics – Claes Lindblad Joins as Chief Financial Officer

Modus Therapeutics – Claes Lindblad Utses till Chief Financial Officer

Modus Therapeutics Announces New Strategy for the Clinical Development of Sevuparin as a Potential Treatment for Sepsis/Septic shock

Modus Therapeutics tillkännager ny strategi för klinisk utveckling av Sevuparin som en potentiell behandling vid sepsis / septisk chock

Notice of Annual General Meeting in Modus Therapeutics Holding AB (Publ) – in Swedish

Modus Therapeutics Announces the Results of its Global, Randomized, Placebo-Controlled Phase 2 Clinical Trial Evaluating Sevuparin for the Management of Acute Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease (SCD)

Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO

First Cohort Dosed in U.S. Phase 1 Study of Subcutaneously Administered Sevuparin

12

Archives

  • March 2021
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • July 2018
  • April 2018
  • March 2018

CONTACT US


Modus Therapeutics AB

Olof Palmes gata 29 IV, 11122 Stockholm, Sweden
CIN 556669-2199
info@modustx.com
Phone: +468 501 370 00
© 2021. Modus Therapeutics AB. All rights reserved.   Privacy & Terms of Use
Go to Top
This web site uses cookies so that we can serve you better. OkPrivacy policy